Realen

Quick links to important sections

Realen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Realen

What is Realen? Identity and General Purpose Overview

The medicine Realen is a synthetic compound widely recognized by its active ingredient, Alendronate (or Alendronic acid). It is specifically used to support and maintain the strength of the skeleton by regulating the balance of bone remodeling.


Property Description
Active ingredient Alendronate sodium
Form Oral tablet, Oral solution, Effervescent tablet
Pharmacological class Bisphosphonate (Anti-resorptive)
General purpose Supports bone strength and density
Origin Synthetic compound

What is Realen and What Class of Drug is It?

Realen is a synthetic pharmaceutical agent belonging to the pharmacological class of bisphosphonates. The active chemical entity, Alendronate, is a nitrogen-containing bisphosphonate (aminobisphosphonate), a classification recognized for its powerful, specific affinity for bone tissue.

The compound is an optimized synthetic analog of natural pyrophosphate. This chemical design allows it to selectively target and bind tightly to mineralized bone surfaces. Alendronate is indicated for bone density conservation, confirming that the medicine is primarily designed to conserve and maintain the mineral structure of the skeleton over time.


Composition and Physical Form of Realen

The active substance in Realen is Alendronate sodium, which is typically prepared as an oral tablet for administration. This means the medication must be taken by mouth to facilitate absorption.

The formulation may vary, encompassing the standard oral tablet, an effervescent tablet that dissolves in water, or an oral solution. The effervescent or liquid formats are options for instances where there may be difficulties swallowing a solid tablet. The overall composition is primarily that of a single active ingredient, though combination products, such as those that include Vitamin D3, also exist.


How Does Realen Generally Help the Body?

Realen works by preserving existing bone mass, thereby helping to increase the strength and resilience of the skeleton. This function is based on its potent anti-resorptive action.

The drug acts by selectively inhibiting the activity of osteoclasts—the specialized cells responsible for the natural breakdown and removal of old bone tissue. By slowing down this rate of bone removal, the drug shifts the biological balance of bone turnover. This action is the basis for its general therapeutic purpose: reducing skeletal loss and supporting the progressive gain in bone density.

Regulatory References

  1. EMA Public Assessment Report for Vantavo (Alendronate)

What side effects are possible with Realen?

Possible Side Effects and Safety Information for Realen (Alendronate)

This summary outlines the adverse reactions and safety characteristics of Realen, based strictly on the documentation provided by government regulatory authorities (e.g., FDA Prescribing Information and European SmPC).

Adverse Reaction Scope

The safety profile is characterized by events categorized primarily by Gastrointestinal Disorders and Musculoskeletal and Connective Tissue Disorders, alongside less common events affecting the nervous system and skin.

Frequency Classification Key Adverse Reactions (Regulatory Examples)
Common ( ge 1/100 ) Abdominal pain, dyspepsia, acid regurgitation, nausea, abdominal distension, constipation, diarrhea, flatulence, headache, muscle/joint pain.
Uncommon ( ge 1/1,000 ) Esophagitis, esophageal ulcers/erosions, gastritis, dysgeusia, rash, erythema.
Rare ( ge 1/10,000 ) Esophageal stricture/perforation, symptomatic hypocalcemia, osteonecrosis of the jaw (ONJ), atypical femoral fractures.

Serious Adverse Reactions (Label-Documented)

The official label documents several serious or clinically significant adverse reactions, including severe esophageal complications (ulceration, perforation), severe and occasionally incapacitating bone, joint, and/or muscle pain, osteonecrosis of the jaw (ONJ), and atypical subtrochanteric and diaphyseal femoral fractures.

Safety Restrictions and Contextual Patterns

  • Population Restrictions: The medicine is officially not recommended for use in patients with severe renal impairment (creatinine clearance less than 35 mL/min). It is also not indicated for use in pediatric patients.
  • Pre-existing Conditions: Caution is advised in patients with active upper gastrointestinal problems (e.g., ulcers, dysphagia), as the drug may worsen the underlying condition.
  • Metabolic Status: Treatment is contraindicated in individuals with hypocalcemia (low blood calcium), which must be corrected prior to therapy initiation.
  • Time-Related Patterns: Transient, influenza-like symptoms (e.g., myalgia, fever, malaise) may be reported primarily at the initiation of treatment. The risk of atypical femoral fractures is documented as potentially associated with long-term exposure.

Regulatory Safety Summary

The official safety information structures the documented risks of Realen around its potential for localized upper GI irritation, classified frequently, contrasted with the regulatory mention of rare but serious skeletal and systemic events. This profile is further defined by formal limitations on its use based on factors such as kidney function, metabolic status, and the presence of esophageal conditions.

Overdose and Emergency Response

Overdose of Realen, containing the active substance Alendronate, is documented to result in two primary types of serious manifestations. The first involves acute metabolic disturbances, specifically hypocalcemia (low calcium levels) and hypophosphatemia (low phosphate levels). The second involves severe upper gastrointestinal adverse reactions due to the drug’s potential to cause corrosive injury. Documented GI symptoms include severe heartburn, nausea, stomach pain, and the potential for esophagitis, gastritis, or ulceration. These severe reactions carry the risk of life-threatening outcomes such as esophageal stricture or perforation.

Regulatory documents mandate immediate emergency action if more than the prescribed dose is taken. The patient must drink a full glass of milk to help bind the drug and reduce absorption, and then contact a local poison control center or emergency room right away. It is explicitly stated that the patient must not attempt to induce vomiting and must remain fully upright. Management of overdose is symptomatic and supportive, often requiring monitoring of serum calcium and phosphate levels to correct any metabolic imbalances.

Therapeutic Uses of Realen

What Realen Treats: Main Uses and Benefits

Realen is generally applied across domains where additional symptomatic support is needed, primarily used in situations involving certain distressing symptoms related to systemic imbalance. It is commonly used to help with symptoms associated with acute or episodic changes, serving as relevant supportive symptom management. This medication is relevant in conditions characterized by periods of heightened symptoms, and may assist with managing symptom clusters that may become intense or disruptive.

The therapeutic domain includes situations involving physical discomfort, systemic imbalance, and symptoms that interfere with daily functioning. Realen is considered relevant in contexts marked by increased discomfort or tension when symptoms create noticeable functional strain. It supports the patient during difficult episodes and assists with maintaining functional stability.

Quick Fact

Quick Fact: Focus on Physical Discomfort and Systemic Imbalance

Realen provides support that helps ease the overall symptom burden during episodes of heightened discomfort. It is used in areas where short-term symptom management is appropriate.

Regulatory References

  1. NIH DailyMed Label for Guaifenesin and Phenylephrine

Eligibility and Restrictions for Use

Who Can and Cannot Use Realen?

The eligibility for using Realen (Alendronate) is strictly determined by specific patient populations and their clinical status, as documented in official regulatory labeling. The medicine is primarily indicated for use in Adults, including postmenopausal women and men diagnosed with osteoporosis, and patients with Paget's Disease of Bone.


Absolute Contraindications

Realen must not be used by patients with a known hypersensitivity to the drug or those with certain abnormalities of the esophagus, such as stricture or achalasia, that delay esophageal emptying. A formal contraindication also applies if a patient is unable to stand or sit upright for at least 30 minutes after taking the tablet. Furthermore, pre-existing hypocalcemia must be corrected before initiating therapy.


Population Restrictions

The drug is not recommended for patients with severe renal impairment, officially defined by a Creatinine Clearance < 35 mL/min, due to limited clinical experience. Use is not indicated for the pediatric population (under 18 years of age). Realen should not be used during pregnancy, and caution is required when prescribing to patients with active upper gastrointestinal problems.

What should I know about interactions with other medicines?

Realen (chlorpheniramine and phenylephrine combination) can interact with a wide range of other medications, potentially increasing side effects or reducing the effectiveness of one or both drugs. It is crucial to inform your healthcare provider of all medicines you are taking, including over-the-counter (OTC) products, vitamins, and herbal supplements.


Major Drug-Drug Interactions

Do not take Realen with Monoamine Oxidase Inhibitors (MAOIs), such as selegiline, isocarboxazid, or linezolid. This combination can lead to a dangerously high increase in blood pressure (hypertensive crisis), which may be life-threatening. The interaction risk persists for up to 14 days after stopping an MAOI.

  • Other Sympathomimetic Agents: Concurrent use with other decongestants (e.g., pseudoephedrine) or appetite suppressants can increase the risk of serious side effects, including elevated heart rate and blood pressure.
  • Central Nervous System (CNS) Depressants: Taking Realen with alcohol, sedatives, tranquilizers, or certain narcotic pain medicines can significantly increase drowsiness, dizziness, and impairment.

Other Important Interactions

Type of Interaction Examples of Interacting Products
Antihypertensive Drugs Methyldopa, beta-blockers, ACE inhibitors
Thyroid Medications Levothyroxine

Phenylephrine in Realen may reduce the effectiveness of medications used to lower blood pressure. Conversely, some thyroid hormones may enhance the effects of phenylephrine, requiring careful monitoring. Always consult a healthcare professional before combining Realen with any other product.

Mechanism of Action

How Realen Works

Realen (Alendronate) operates through a highly targeted mechanism focused on the bone-remodeling cycle, functioning as an anti-resorptive compound.


Inhibition of the FDPS Enzyme in Osteoclasts

The active compound is selectively internalized by bone-resorbing cells, osteoclasts, where it acts as a specific inhibitor of the enzyme Farnesyl Diphosphate Synthase (FDPS). This enzymatic block impairs the cell's ability to maintain its structure and signaling, leading to osteoclast dysfunction and subsequent apoptosis.


Modulation of Skeletal Homeostasis

The suppression of activity and survival of osteoclasts alters the balance of bone turnover. This sustained reduction in the rate of bone removal allows the existing bone formation processes to dominate. The physiological outcome is an altered bone mass balance, resulting in an increase in Bone Mineral Density (BMD).


Mechanistic Support and Mineral Substrate

When combined with Vitamin D3, the Vitamin D3 component acts on calcium homeostasis, supporting adequate mineral substrate availability. This action provides the mineral substrate necessary for the consolidation of the preserved bone structure.

Dosage and Administration Information

Realen, containing the active substance Alendronate, is administered exclusively by the oral route and is subject to strict positional and time-of-day requirements to ensure proper delivery and absorption. The standard usage patterns are defined by either a once-daily or once-weekly schedule. For instance, the treatment of postmenopausal osteoporosis typically uses a 70 mg dose taken once every week.

Administration Protocol and Context

Proper usage mandates the tablet or solution be taken immediately upon arising for the day. This must occur at least 30 minutes before any consumption of food, beverages other than plain water, or other oral medications. Absorption is significantly reduced by fluids like coffee, juice, or mineral water, which are avoided during this critical period.

The medication must be swallowed using a full glass of plain water (approximately 200 mL). Following administration, individuals must remain fully upright—sitting or standing—for a minimum of 30 minutes, and until after the first food of the day. This procedural constraint is necessary to facilitate delivery past the esophagus.

Dosage strengths commonly include 5 mg and 10 mg for daily use, and 35 mg and 70 mg for weekly use, with 40 mg reserved for specific conditions like Paget's disease over a 6-month course. The use of Alendronate is not advised for patients with severe renal impairment (creatinine clearance less than 35 mL/min).

Handling of Missed Dosing

If a weekly dose is forgotten, it should be taken the next morning it is remembered; however, two doses must never be taken on the same day. The patient should then revert to the original scheduled day for the following week.

Recent Clinical Evidence

Research evidence / Overview of studies for Realen (Alendronate)

The research evidence for Realen, whose active ingredient is Alendronate, centers on its use for managing bone density. This evidence is primarily derived from Randomized Controlled Trials (RCTs) and systematic reviews.


Evidence for use in Osteoporosis in Postmenopausal Women

The largest body of research was evaluated in women after menopause who have osteoporosis. These studies tracked changes in Bone Mineral Density (BMD) at the spine and hip, and the incidence of new vertebral and hip fractures. For women considered high-risk, the studies described patterns observed where the incidence of new clinical vertebral fractures was lower in the treatment group compared to the placebo group. Research also highlights changes measured during the study period; studies reported measurements of higher average BMD at the hip and spine. However, data concerning non-vertebral fractures in lower-risk groups often exhibited variability and imprecision.


Evidence in Other Populations: Men and Glucocorticoid Use

Realen was evaluated in studies involving adults receiving long-term treatment with glucocorticoids (steroids), which is a known cause of bone loss. Across these trials, data showed patterns related to measurements of preserved or increased BMD in the treatment groups when compared to placebo. Similarly, the research landscape includes dedicated RCTs where Realen was studied for men diagnosed with osteoporosis, showing BMD measurements that generally followed the same pattern of preservation. However, the total volume of dedicated research data for men is lower, and long-term fracture reduction data is less extensive.


Research Gaps and Areas of Uncertainty

Long-term effects beyond ten years are not fully established, and limited information exists about the long-term clinical outcomes for those who stop treatment after many years. The evidence for certain groups, such as younger adults or those with specific comorbidities, remains limited. The research provides context but does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group

Frequently Asked Questions (FAQ)

Common questions about Realen (FAQ)


Q: How quickly does Realen start to work after taking it?

Regulatory information indicates that Realen is designed to act on bone tissue by binding quickly to the bone surface. While this action begins quickly, the measurable clinical benefit, such as a full increase in Bone Mineral Density (BMD), is typically observed after 6 to 12 months of consistent therapy.

Q: Does Realen interact with alcohol?

Official regulatory documents typically do not list a direct chemical interaction between Realen and alcohol. However, excessive alcohol use is noted as a factor that may potentially compound the risk of gastrointestinal irritation, which is a key potential side effect of the medication. Additionally, heavy alcohol consumption is known to negatively impact overall bone health.

Q: Can I drink coffee after the 30-minute waiting period when taking Realen?

The official product information specifies that all beverages other than plain water must be avoided during the 30-minute period immediately after taking Realen. Once this critical window has passed and the first food of the day has been consumed, the concern for interaction with beverages like coffee is reduced.

Q: What happens if you miss a dose of Realen?

The action for a missed dose depends on the prescribed schedule. If a daily dose is missed, it should be skipped, and the regular schedule continued the next morning. If a weekly dose is remembered on a different morning, it may be taken then; however, the instruction is not to take two doses on the same day.

Q: Is Realen addictive?

Realen (Alendronate) is a bisphosphonate that works on bone tissue. It is not classified as a controlled substance and official sources confirm it has no potential for abuse or dependence.

Q: Do you get withdrawal symptoms if you stop taking Realen suddenly?

Realen is not associated with classic withdrawal symptoms like cravings or physical distress. Because the medication binds tightly to the bone, its effects diminish slowly over time after treatment is stopped. The process does not typically involve a physical withdrawal syndrome.

Q: Is it normal to feel a mild headache when starting Realen?

According to clinical trial data, headache is listed as a common adverse reaction of Realen. Furthermore, official information notes that transient, flu-like symptoms (including general malaise or feeling unwell) may be reported, often in association with the start of treatment.

Q: Does Realen affect your energy levels?

Official adverse reaction reports do not commonly list fatigue or increased energy as direct effects of Realen. However, some patients have reported transient symptoms of asthenia (weakness) or general malaise, which could potentially impact perceived energy levels, primarily at the beginning of treatment.

Q: Is it safe to take Realen if I have high blood pressure?

High blood pressure is not listed as an absolute contraindication for Realen. However, official information lists drug interactions with certain anti-hypertensive medications (used to treat high blood pressure). Due to potential interactions, it is important for a healthcare provider to review the patient's entire medication regimen, especially when anti-hypertensive drugs are involved.

Q: Are there any cosmetic changes, like hair loss or skin issues, linked to Realen?

Official regulatory sources report that cosmetic changes like alopecia (hair loss or thinning), and various skin reactions (rashes, redness) have been noted in post-marketing experience. These are not common side effects, but any such occurrences are typically reported to a medical professional.

Q: What should I do if the side effects of Realen are bothersome?

The Patient Information sheet provides instructions for patients to contact their healthcare provider if side effects are bothersome. Official guidance also encourages the reporting of suspected adverse reactions to the relevant regulatory authority.

Q: How long does Realen stay in your system?

Realen is rapidly cleared from the bloodstream, but it binds very strongly to bone mineral. Because of this strong binding, the drug's activity can remain in the bone tissue for an extended period, with an estimated terminal elimination half-life of over 10 years.

Q: Is there a maximum time frame for safely taking Realen?

Official regulatory information notes that the optimal duration of use has not been definitively established. The prescribing information advises that patients at low risk for fracture should have the need for continued therapy re-evaluated on a periodic basis, with consideration given to temporarily stopping the drug after 3 to 5 years of use.

Q: Can Realen make you sensitive to sunlight?

Official adverse event reports mention that rare cases of rash with photosensitivity (sensitivity to light) have been reported. If an unusual skin reaction or severe sun sensitivity is noticed while taking Realen, it is important for a medical professional to be informed.

Q: Can I take Realen with vitamins or mineral supplements?

The absorption of Realen is significantly reduced by supplements containing minerals such as calcium or iron. To prevent this interference, these supplements must be taken at a different time, generally at least 30 minutes after your dose of Realen.

Q: What happens if I accidentally take two doses of Realen close together?

In the event of an accidental overdose, the official product information advises measures such as drinking a full glass of milk or taking an antacid, and instructs not to lie down. Patients are directed to contact a poison control center or seek emergency medical services immediately for guidance.

Q: Does Realen interact with cold and flu medications?

Interactions may occur with certain components of cold and flu medications. Any over-the-counter pain relievers (like NSAIDs) used for cold/flu symptoms should be reviewed as they may increase the risk of stomach irritation when combined with Realen. Additionally, antacids or mineral-containing ingredients must be separated from your dose.

Q: Is it a common practice to combine Realen with other treatments?

Official prescribing information recommends that patients who do not get enough calcium and Vitamin D from their diet should take supplements. This indicates that combining Realen with Vitamin D and calcium is a common practice to ensure the body has the necessary mineral support for bone health.

Q: How does Realen differ from placebo in clinical trials?

Clinical trials showed that Realen was more effective than placebo (an inactive substance) in improving bone health outcomes. It resulted in a larger increase in bone mineral density and significantly reduced the incidence of critical fractures, such as those in the hip and spine, compared to the placebo group.

Q: Are there different strengths or forms of Realen?

Official dosage form information confirms that Realen is available in several oral dosage forms and strengths. These include different concentrations of oral tablets (e.g., 5 mg, 10 mg, 35 mg, 70 mg) and an oral solution, providing flexibility for different patient needs.

How should Realen be stored and disposed of?

How to Store Realen

The medicine Realen (Alendronate) must be stored strictly according to the conditions mandated in the official prescribing information to preserve its stability.

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature (e.g., 15 C to 30 C or 59 F to 86 F).
Prohibitions Keep from freezing and store away from heat and direct light.
Packaging Keep in the original, tightly closed container or blister pack to protect it from moisture. Effervescent tablets must remain in the blister until use.
Safety It is mandatory to keep this and all drugs out of the sight and reach of children.

How to Dispose of Realen

When Realen is expired or no longer needed, it should be disposed of in accordance with local regulations or via a pharmaceutical take-back program. Disposal instructions advise consulting a healthcare professional or pharmacist for guidance. The official labeling confirms that the product does not require any special precautions or handling as hazardous or cytotoxic waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Realen found in:

A-Z Index: